|
Jun 12
|
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
|
|
Jun 11
|
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
|
|
Jun 11
|
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
|
|
May 31
|
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
|
|
May 27
|
Sector Update: Health Care Stocks Rise Premarket Tuesday
|
|
May 27
|
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
|
|
May 27
|
BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer
|
|
May 27
|
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
|
|
May 22
|
Exploring US High Growth Tech Stocks In May 2025
|
|
May 22
|
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
|
|
Apr 17
|
BeiGene to Announce First Quarter 2025 Financial Results on May 7
|
|
Apr 3
|
BeiGene halts ociperlimab amid poor Phase III trial predictions
|
|
Apr 3
|
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
|
|
Mar 31
|
Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value
|
|
Mar 31
|
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
|
|
Mar 21
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Mar 18
|
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
|
|
Feb 21
|
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50
|
|
Feb 21
|
US Stocks Trading Below Estimated Value In February 2025
|
|
Feb 21
|
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
|